| Technical Name | Ligands selective to alpha 6 subunit-containing GABAA receptorstheir methods of use | ||
|---|---|---|---|
| Project Operator | National Taiwan University | ||
| Project Host | 邱麗珠 | ||
| Summary | An international collaboration led by Prof. Lih-Chu Chiou, College of Medicine, National Taiwan University, has identified a novel promising drug candidate, the α6-containing GABAA receptor-selective positive allosteric modulator, for the treatment of migraine, trigeminal painneuropsychiatric disorders (schizophreniaTourette syndrome). | ||
| Market Potential Analysis | 目前市面上無專一作用於此特定胺基丁酸甲類亞型受體的藥品，因而可針對那些對傳統藥物治療無效之病人提供全新的治療選擇。 | ||
| Industrial Applicability | The candidate compound has promising safety pharmacologypharmacokineticsmay emerge as novel drug candidate for above diseases. It is ready to enter pre-clinical IND-enabling studies. If successfully approved in the future, it would provide the first-in-classsafe medicinal therapy to the patients inflicted with the mentioned diseases. | ||
| Keyword | First-in-class GABA-A receptor positive allosteric modulator migraine trigeminal pain neuropsychiatric disorders schizophrenia Tourette syndrome orphan drug excellent pharmacokinetics | ||
- pamelapan101@gmail.com
Other people also saw
